1. Academic Validation
  2. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo

  • Clin Cancer Res. 2007 Sep 1;13(17):5183-94. doi: 10.1158/1078-0432.CCR-07-0161.
Joell J Gills 1 Jaclyn Lopiccolo Junji Tsurutani Robert H Shoemaker Carolyn J M Best Mones S Abu-Asab Jennifer Borojerdi Noel A Warfel Erin R Gardner Matthew Danish M Christine Hollander Shigeru Kawabata Maria Tsokos William D Figg Patricia S Steeg Phillip A Dennis
Affiliations

Affiliation

  • 1 Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA.
Abstract

Purpose: The development of new Cancer drugs is slow and costly. HIV Protease Inhibitors are Food and Drug Administration approved for HIV patients. Because these drugs cause toxicities that can be associated with inhibition of Akt, an emerging target in Cancer, we assessed the potential of HIV Protease Inhibitors as Anticancer agents.

Experimental design: HIV Protease Inhibitors were screened in vitro using assays that measure cellular proliferation, apoptotic and nonapoptotic cell death, endoplasmic reticulum (ER) stress, Autophagy, and activation of Akt. Nelfinavir was tested in non-small cell lung carcinoma (NSCLC) xenografts with biomarker assessment.

Results: Three of six HIV Protease Inhibitors, nelfinavir, ritonavir, and saquinavir, inhibited proliferation of NSCLC cells, as well as every cell line in the NCI60 cell line panel. Nelfinavir was most potent with a mean 50% growth inhibition of 5.2 micromol/L, a concentration achievable in HIV patients. Nelfinavir caused two types of cell death, caspase-dependent Apoptosis and caspase-independent death that was characterized by induction of ER stress and Autophagy. Autophagy was protective because an inhibitor of Autophagy increased nelfinavir-induced death. Akt was variably inhibited by HIV Protease Inhibitors, but nelfinavir caused the greatest inhibition of endogenous and growth factor-induced Akt activation. Nelfinavir decreased the viability of a panel of drug-resistant breast Cancer cell lines and inhibited the growth of NSCLC xenografts that was associated with induction of ER stress, Autophagy, and Apoptosis.

Conclusions: Nelfinavir is a lead HIV Protease Inhibitor with pleiotropic effects in Cancer cells. Given its wide spectrum of activity, oral availability, and familiarity of administration, nelfinavir is a Food and Drug Administration-approved drug that could be repositioned as a Cancer therapeutic.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》